Author(s): Tamara Moyo, Jeanne Palmer, Yi Huang, et al. Abstract: S133 Session topic: 16. Myeloproliferative neoplasms – Clinical Background JAK inhibition with ruxolitinib (rux) reduces spleen size and myelofibrosis (MF)-related symptoms and improves survival, but nearly half of responders relapse within 5 years. Treatment options for MF after failure of rux are...
Pro zobrazení tohoto obsahu je třeba být přihlášen.